NV-5138
NV-5138 is an experimental drug currently under development for the treatment of Major Depressive Disorder (MDD) and other Mental Disorders. It is being developed by the biopharmaceutical company Naurex, a subsidiary of Allergan.
Mechanism of Action[edit | edit source]
NV-5138 acts as a selective mTORC1 activator. mTORC1, or mechanistic target of rapamycin complex 1, is a protein complex that controls protein synthesis and has been implicated in a variety of diseases, including depression. By activating mTORC1, NV-5138 is thought to stimulate the synthesis of proteins that are necessary for the formation of new synaptic connections in the brain, a process known as synaptogenesis. This is believed to result in an antidepressant effect.
Clinical Trials[edit | edit source]
NV-5138 has undergone Phase 1 Clinical Trials to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers. The results of these trials have not yet been published. Phase 2 trials are planned to further evaluate the drug's efficacy and safety in patients with MDD.
Potential Advantages[edit | edit source]
NV-5138 has several potential advantages over existing treatments for MDD. Firstly, it has a novel mechanism of action, which may make it effective in patients who have not responded to other treatments. Secondly, it is taken orally, which may make it more convenient than treatments that require injection. Finally, preliminary data suggest that it may have a rapid onset of action, potentially providing relief from depressive symptoms within hours or days rather than weeks.
Potential Disadvantages[edit | edit source]
As with any experimental drug, there are potential disadvantages and risks associated with NV-5138. These include the possibility of unknown side effects, the potential for drug interactions, and the risk that the drug may not be effective in treating MDD. Furthermore, the drug's long-term safety profile has not yet been established.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
